Chicago, IL – June 11, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Johnson & Johnson JNJ, T-Mobile US, Inc. TMUS, The Boeing Co. BA and Franklin Financial Services Corp. FRAF.
Here are highlights from Tuesday’s Analyst Blog:
The Zacks Research Daily presents the best research output of our analyst team. Today’s Research Daily features new research reports on 16 major stocks, including Johnson & Johnson, T-Mobile US, Inc., and The Boeing Co., as well as one micro-cap stock, Franklin Financial Services Corp.. The Zacks microcap research is unique, as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
The daily ‘Ahead of Wall Street’ article is a must-read for all investors who would like to be ready for that day’s trading action. The article comes out before the market opens and attempts to make sense of that morning’s economic releases and how they will affect that day’s market action. You can read this article for free on our home page, and can actually sign up there to get an email notification as this article comes out each morning.
You can read today’s AWS here >>> Pre-Market Futures Have Fingers Crossed for Trade Deals
Shares of Johnson & Johnson have gained +5.8% over the past year against the Zacks Large Cap Pharmaceuticals industry’s decline of -15.4%. The company’s Innovative Medicine unit is showing a growth trend, driven by existing products like Darzalex, Tremfya and Erleada, and continued uptake of new launches, including Spravato, Carvykti and Tecvayli. J&J is making rapid progress with its pipeline and has been on an acquisition spree lately, which has strengthened its pipeline.
Advertisement: High Yield Savings Offers
However, sales in the MedTech segment have slowed down due to headwinds in Asia-Pacific markets like China and competitive pressure in some categories. The launch of Stelara generics is eroding the drug’s sales in 2025. Uncertainty around talc lawsuits remains.
(You can read the full research report on Johnson & Johnson here >>>)
link
